By using integrated analyses of gene expression profiles from microarray (samples: PBMCs from AMI patients), single-cell RNA-sequencing (scRNA-seq, samples: recruited monocytes/macrophages from AMI mice) and bulk RNA-sequencing (bulk RNA-seq, samples: cardiac macrophages from AMI mice), we identified 3 key genes CUX1, CTSD, and ADD3 as potential biomarkers for early recognizing AMI patients at risk of developing HF. This evidence concerns the gene ADD3 and hydrops fetalis.